Driven by GLP-1s, pharma’s relationship with consumers is starting to change

Pharmaceutical companies’ ability to interact with the patients taking their medications has changed over the last few years. The rise of direct-to-consumer channels, driven largely by consumer willingness to pay for GLP-1s for weight loss ...